A Phase 1 interventional study of Orforglipron and Midazolam in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants.
The study will last up to approximately 8 weeks including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a level of:
Exclusion Criteria:
Have known allergies to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received: * Day -1: single dose of 0.2 milligram (mg) midazolam. * Day 1: single dose of 1 mg orforglipron. * Days 5 to 6: 200 mg quinidine twice daily (BID). * Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam. * Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
Drug: Orforglipron · Drug: Midazolam · Drug: Quinidine
Administered orally
Also known as: LY3502970
Administered orally
Administered orally
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron
PK: AUC0-inf of Orforglipron.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8
PK: Maximum Observed Concentration (Cmax) of Orforglipron
PK: Cmax of Orforglipron.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam
PK: AUC0-inf of Midazolam.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
PK: Maximum Concentration (Cmax) of Midazolam
PK: Cmax of Midazolam.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam
PK: AUC0-inf of 1-Hydroxymidazolam (metabolite of Midazolam).
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
PK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam
PK: Cmax of 1-Hydroxymidazolam (metabolite of Midazolam).
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
| Milestone | Midazolam + Orforglipron + Quinidine |
|---|---|
| Started | 27 |
| Received at least one dose of study drug | 27 |
| Completed | 27 |
| Not completed | 0 |
PK: AUC0-inf of Orforglipron.
| nanogram*hour per milliliter | Midazolam + Orforglipron + Quinidine |
|---|---|
| Day 1 | 89.9 ± 30.4 |
| Day 8 | 79.1 ± 30.2 |
PK: Cmax of Orforglipron.
| nanogram per milliliter | Midazolam + Orforglipron + Quinidine |
|---|---|
| Day 1 | 4.11 ± 32.2 |
| Day 8 | 3.06 ± 39.6 |
PK: AUC0-inf of Midazolam.
| nanogram*hour per milliliter | Midazolam + Orforglipron + Quinidine |
|---|---|
| Day -1 | 2.06 ± 41.7 |
| Day 7 | 2.73 ± 42.1 |
PK: Cmax of Midazolam.
| nanogram per milliliter | Midazolam + Orforglipron + Quinidine |
|---|---|
| Day -1 | 0.725 ± 35.2 |
| Day 7 | 0.999 ± 49.2 |
PK: AUC0-inf of 1-Hydroxymidazolam (metabolite of Midazolam).
| nanogram*hour per milliliter | Midazolam + Orforglipron + Quinidine |
|---|---|
| Day -1 | 0.676 ± 39.2 |
| Day 7 | 0.999 ± 38 |
PK: Cmax of 1-Hydroxymidazolam (metabolite of Midazolam).
| nanogram per milliliter | Midazolam + Orforglipron + Quinidine |
|---|---|
| Day -1 | 0.224 ± 39.6 |
| Day 7 | 0.343 ± 50.5 |
Collected over Day -1 through the end of study (Up To 21 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.2 mg Midazolam (Day -1) | 0/27 (0%) | 0/27 (0%) | 4/27 (14.8%) |
| 1 mg Orforglipron (Days 1 to 4) | 0/27 (0%) | 0/27 (0%) | 7/27 (25.9%) |
| 200 mg Quinidine BID (Days 5 to 6) | 0/27 (0%) | 0/27 (0%) | 6/27 (22.2%) |
| 200 mg Quinidine BID + 0.2mg Midazolam (Day 7) | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| 200mg Quinidine BID + 1mg Orforglipron (Day 8 to End of Study) | 0/27 (0%) | 0/27 (0%) | 7/27 (25.9%) |
| Event | 0.2 mg Midazolam (Day -1) | 1 mg Orforglipron (Days 1 to 4) | 200 mg Quinidine BID (Days 5 to 6) | 200 mg Quinidine BID + 0.2mg Midazolam (Day 7) | 200mg Quinidine BID + 1mg Orforglipron (Day 8 to End of Study) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/27 | 3/27 | 0/27 | 0/27 | 1/27 |
| Abdominal painGastrointestinal disorders | 0/27 | 0/27 | 2/27 | 0/27 | 1/27 |
| HeadacheNervous system disorders | 2/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| PalpitationsCardiac disorders | 0/27 | 0/27 | 0/27 | 1/27 | 1/27 |
| Dry eyeEye disorders | 0/27 | 1/27 | 0/27 | 0/27 | 0/27 |
| Vision blurredEye disorders | 0/27 | 0/27 | 1/27 | 0/27 | 0/27 |
| Abdominal distensionGastrointestinal disorders | 0/27 | 1/27 | 0/27 | 0/27 | 1/27 |
| DiarrhoeaGastrointestinal disorders | 0/27 | 0/27 | 1/27 | 0/27 | 1/27 |
| FlatulenceGastrointestinal disorders | 0/27 | 1/27 | 0/27 | 0/27 | 0/27 |
| Rectal tenesmusGastrointestinal disorders | 0/27 | 1/27 | 0/27 | 0/27 | 0/27 |
All enrolled participants.
| Age, Continuous(years) | Midazolam + Orforglipron + Quinidine |
|---|---|
| Mean | 35.3 ± 9.3 |
| Sex: Female, Male(Participants) | Midazolam + Orforglipron + Quinidine |
|---|---|
| Female | 13 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | Midazolam + Orforglipron + Quinidine |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Midazolam + Orforglipron + Quinidine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 22 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Midazolam + Orforglipron + Quinidine |
|---|---|
| United States | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2024 to primary completion in Feb 2025, 1 month.
Results were first posted in May 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron